The most remarkable results were the LATS2 increased expression in CML subjects, the augmented expression of TAZ in CML subjects at advanced phases, and the increased TAZ expression in CML IM-resistant patients [199]. This evidence concerns the gene WWTR1 and chronic myelogenous leukemia, BCR-ABL1 positive.